Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT03901378
Title Pembrolizumab With Chemotherapy in Metastatic or Unresectable High Grade Gastroenteropancreatic or Lung Neuroendocrine Carcinoma
Recruitment Withdrawn
Gender both
Phase Phase II
Variant Requirements No
Sponsors Ochsner Health System
Indications

gastrointestinal neuroendocrine tumor

large cell neuroendocrine carcinoma

pancreatic endocrine carcinoma

Therapies

Carboplatin + Etoposide + Pembrolizumab

Pembrolizumab

Cisplatin + Etoposide + Pembrolizumab

Age Groups: senior | adult
Covered Countries USA

Facility Status City State Zip Country Details
Ochsner Clinic Foundation Kenner Louisiana 70065 United States Details
Ochsner Clinic Foundation New Orleans Louisiana 70121 United States Details
*Shaded cells indicate that there was no data available from clincialtrials.gov for the field